Aurobindo Pharma gets license from BMS for two ARV products

Mumbai, Mar 17 (UNI) Aurobindo Pharma has announced that it has been given the license to market Stavudine and Didanosine, two important antiretrovirals (ARV) by Bristol-Myers Squibb company.

Announcing this to BSE today, the company said one of the objectives of this license is to increase access of the products for the benefit of the people in the aforesaid territory specifically for the treatment of HIV/AIDS.

The company has the largest number of approved products by US Food and Drug Administration (FDA) for the ARV segment and continues to play an anchor role in the management of AIDS by supply APIs anf formulations for most of the antiretrovirals.

UNI SN MJ SKB1611